Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Raman, Marine C C ^a   Rizkallah, Pierre J ^b   Simmons, Ruth ^a   Donnellan, Zoe ^a   Dukes, Joseph ^a   Bossi, Giovanna ^a   Le Provost, Gabrielle S ^a   Todorov, Penio ^a   Baston, Emma ^a   Hickman, Emma ^a   Mahon, Tara ^a   Hassan, Namir ^a   Vuidepot, Annelise ^a   Sami, Malkit ^a   Cole, David K ^b   Jakobsen, Bent K ^a  

^a Immunocore Limited   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIN; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; MAGEA3 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN BINDING; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR PROTEIN;

ADVERSE EFFECTS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CARDIOTOXICITY; CELL LINE; CHEMISTRY; CROSS REACTION; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULAR MIMICRY; MOLECULAR MODEL; MUTATION; PROCEDURES; PROTEIN CONFORMATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CARDIOTOXICITY; CELL LINE; CONNECTIN; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; MODELS, MOLECULAR; MOLECULAR MIMICRY; MUTATION; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS;

EID: 84955077846     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18851     Document Type: Article

References (50)

1. Garboczi, D. N. et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384, 134-141 (1996).
2. Cole, D. K. et al. Human TCR-binding affinity is governed by MHC class restriction. J. Immunol. 178, 5727-34 (2007).
3. Aleksic, M. et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42, 3174-9 (2012).
4. Garrido, F., Cabrera, T., Aptsiauri, N. 'Hard' and 'soft' lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 127, 249-56 (2010).
5. Cole, D. K. et al. Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Front. Immunol. 4, 168 (2013).
6. Dunn, S. M. et al. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 15, 710-21 (2006).
7. Li, Y. et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23, 349-54 (2005).
8. Holler, P. D., Chlewicki, L. K., Kranz, D. M. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4, 55-62 (2003).
9. Kieke, M. C. et al. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc. Natl. Acad. Sci. USA 96, 5651-6 (1999).
10. Irving, M. et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J. Biol. Chem. 287, 23068-78 (2012).
11. Varela-Rohena, A. et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14, 1390-5 (2008).
12. Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood (2013).
13. van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254. 1643-7 (1991).
14. Karanikas, V. et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J. Immunol. 171, 4898-904 (2003).
15. Cameron, B. J. et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197-103 (2013).
16. Mason, D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19, 395-404 (1998).
17. Sewell, A. K. Why must T cells be cross-reactive Nat. Rev. Immunol. 12, 669-77 (2012).
18. Wooldridge, L. et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 287, 1168-77 (2012).
19. Birnbaum, M. E. et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157, 1073-87 (2014).
20. Rudolph, M. G., Stanfield, R. L., Wilson, I. A. How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24, 419-66 (2006).
21. Cole, D. K. et al. T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J. Biol. Chem. 289, 628-38 (2014).
22. Madura, F. et al. T-cell receptor specificity maintained by altered thermodynamics. J. Biol. Chem. 288, 18766-75 (2013).
23. Madura, F. et al. Structural basis for ineffective T-cell responses to MHC anchor residue-improved 'heteroclitic' peptides. Eur. J. Immunol. 45, 584-91 (2015).
24. Cole, D. K. et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J. Immunol. 185, 2600-10 (2010).
25. Tickle, I. J., Laskowski, R. A., Moss, D. S. Rfree and the rfree ratio. II. Calculation Of the expected values and variances of crossvalidation statistics in macromolecular least-squares refinement. Acta Crystallogr. D. Biol. Crystallogr. 56, 442-50 (2000).
26. Sami, M. et al. Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Protein Eng. Des. Sel. 20, 397-403 (2007).
27. Rossjohn, J. et al. T Cell Antigen Receptor Recognition of Antigen-Presenting Molecules. Annu. Rev. Immunol. (2014).
28. Miles, J. J. et al. Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog. 6. e1001198. (2010).
29. Bridgeman, J. S., Sewell, A. K., Miles, J. J., Price, D. A., Cole, D. K. Structural and biophysical determinants of T-cell antigen recognition. Immunology 135, 9-18 (2012).
30. Adams, J. J. et al. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity 35, 681-693 (2011).
31. Reiser, J.-B. et al. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat. Immunol. 4, 241-7 (2003).
32. Reiser, J. B. et al. Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat. Immunol. 1, 291-7 (2000).
33. Sethi, D. K., Gordo, S., Schubert, D. A., Wucherpfennig, K. W. Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop. Nat. Commun. 4, 2623 (2013).
34. Holland, C. J. et al. Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Sci. Rep. 2, 629 (2012).
35. Colf, L. A. et al. How a single T cell receptor recognizes both self and foreign MHC. Cell 129, 135-146 (2007).
36. von Herrath, M. G., Fujinami, R. S., Whitton, J. L. Microorganisms and autoimmunity: making the barren field fertile Nat. Rev. Microbiol. 1, 151-7 (2003).
37. Cole, D. K. et al. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol. Immunol. 45, 2700-9 (2008).
38. Boulter, J. M. et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 16, 707-11 (2003).
39. Liddy, N. et al. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18, 980-7 (2012).
40. Bulek, A. M. et al. Structural basis for the killing of human beta cells by CD8(+ ) T cells in type 1 diabetes. Nat. Immunol. 13, 283-9 (2012).
41. Cole, D. K. et al. Computational design and crystal structure of an enhanced affinity mutant human CD8 alphaalpha coreceptor. Proteins 67, 65-74 (2007).
42. Karlsson, R., Katsamba, P. S., Nordin, H., Pol, E., Myszka, D. G. Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem. 349, 136-47 (2006).
43. Bulek, A. M. et al. TCR/pMHC Optimized Protein crystallization Screen. J. Immunol. Methods 382, 203-10 (2012).
44. Kabsch, W. XDS. Acta Crystallogr. D. Biol. Crystallogr. 66, 125-32 (2010).
45. Winter, G., Lobley, C. M. C., Prince, S. M. Decision making in xia2. Acta Crystallogr. D. Biol. Crystallogr. 69, 1260-73 (2013).
46. Collaborative Computational Project, N. 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D. Biol. Crystallogr. 50, 760-3 (1994).
47. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
48. Emsley, P., Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126-32 (2004).
49. Purbhoo, M. A., Irvine, D. J., Huppa, J. B., Davis, M. M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5, 524-30 (2004). URL https://www.pymol.org/
50. Purbhoo, M. A., Irvine, D. J., Huppa, J. B., Davis, M. M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5, 524-30. 2004